Pharmacogenomics Market Analysis Report 2022 to 2028
Pharmacogenomics Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 7.09 Billion |
| Market Size by 2028 | US$ 14.11 Billion |
| Global CAGR (2021 - 2028) | 10.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Pharmacogenomics Market – Segmentation
- Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is further segmented into standard PCR, real time PCR, and digital PCR.
- By application, the pharmacogenomics market is segmented into drug discovery, oncology, neurology and psychiatry, pain management, cardiovascular diseases, and others.
- Based on end User, the pharmacogenomics market is segmented into hospitals and clinics, biopharmaceutical companies, CROs and CDMOs, and others.
- By Geography, the intradermal injection market is segmented in North America (the US, Canada, and Mexico), Europe (France, Germany, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, India, Japan, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).
F. Hoffmann-la Roche Ltd; Abbott; Oxford Nanopore Technologies; Thermo Fisher Scientific Inc; Illumina, Inc; QIAGEN; Agilent Technologies, Inc; Myriad Genetics, Inc; Admera Health; and Dynamic DNA Laboratories are a few companies operating in the pharmacogenomic market.
Get Free Sample For